Jefferies Financial Group Reiterates "Hold" Rating for CureVac (NASDAQ:CVAC)

Jefferies Financial Group reiterated their hold rating on shares of CureVac (NASDAQ:CVAC - Free Report) in a research note issued to investors on Friday morning, MarketBeat reports. The brokerage currently has a $5.00 price objective on the stock, down from their prior price objective of $7.00.

Several other research analysts have also recently issued reports on CVAC. JMP Securities reiterated a "market outperform" rating and issued a $10.00 price objective on shares of CureVac in a research report on Wednesday, May 28th. UBS Group decreased their price objective on shares of CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th.

CureVac Stock Performance

CVAC stock traded down $0.05 during trading on Friday, hitting $5.52. The company had a trading volume of 1,500,133 shares, compared to its average volume of 993,357. The firm has a 50-day moving average price of $3.76 and a 200-day moving average price of $3.49. CureVac has a 1-year low of $2.37 and a 1-year high of $5.72. The firm has a market cap of $1.24 billion, a PE ratio of 10.04 and a beta of 2.49. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). The firm had revenue of $0.94 million during the quarter, compared to analyst estimates of $4.27 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, analysts expect that CureVac will post 0.72 earnings per share for the current year.

Institutional Investors Weigh In On CureVac

A number of large investors have recently bought and sold shares of the stock. Signaturefd LLC raised its stake in CureVac by 29.2% in the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company's stock valued at $123,000 after purchasing an additional 8,170 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of CureVac by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after buying an additional 22,491 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of CureVac by 61.8% in the fourth quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company's stock valued at $171,000 after buying an additional 19,098 shares during the last quarter. Barclays PLC lifted its stake in shares of CureVac by 51.8% during the fourth quarter. Barclays PLC now owns 34,836 shares of the company's stock valued at $118,000 after buying an additional 11,890 shares during the period. Finally, XTX Topco Ltd boosted its position in CureVac by 90.2% during the fourth quarter. XTX Topco Ltd now owns 24,365 shares of the company's stock worth $83,000 after acquiring an additional 11,553 shares during the last quarter. Institutional investors and hedge funds own 17.26% of the company's stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.